Norris Financial Group LLC bought a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 342,477 shares of the biotechnology company’s stock, valued at approximately $5,076,000. Aurinia Pharmaceuticals makes up approximately 1.7% of Norris Financial Group LLC’s investment portfolio, making the stock its 18th biggest holding.
A number of other hedge funds and other institutional investors also recently made changes to their positions in AUPH. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Aurinia Pharmaceuticals by 213.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock valued at $37,283,000 after buying an additional 2,297,903 shares during the last quarter. Marshall Wace LLP raised its position in Aurinia Pharmaceuticals by 1,272.5% during the third quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock valued at $16,389,000 after acquiring an additional 1,375,072 shares in the last quarter. Kotler Kevin acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $19,536,000. Two Sigma Investments LP grew its position in Aurinia Pharmaceuticals by 728.6% in the third quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock worth $14,819,000 after acquiring an additional 1,179,219 shares in the last quarter. Finally, Man Group plc increased its stake in shares of Aurinia Pharmaceuticals by 368.9% during the 4th quarter. Man Group plc now owns 852,671 shares of the biotechnology company’s stock worth $13,600,000 after purchasing an additional 670,812 shares during the last quarter. 36.83% of the stock is owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Trading Down 1.2%
NASDAQ:AUPH opened at $15.00 on Friday. Aurinia Pharmaceuticals Inc has a 12 month low of $8.85 and a 12 month high of $19.25. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of 6.91 and a beta of 1.41. The company has a quick ratio of 5.01, a current ratio of 5.55 and a debt-to-equity ratio of 0.08. The company’s 50 day moving average is $15.95 and its 200-day moving average is $15.35.
Analysts Set New Price Targets
A number of brokerages recently issued reports on AUPH. Zacks Research cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings downgraded Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $17.33.
Check Out Our Latest Stock Report on AUPH
Insider Transactions at Aurinia Pharmaceuticals
In other Aurinia Pharmaceuticals news, CEO Kevin Tang purchased 206,005 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were bought at an average cost of $15.28 per share, with a total value of $3,147,756.40. Following the completion of the transaction, the chief executive officer owned 13,044,106 shares in the company, valued at $199,313,939.68. This trade represents a 1.60% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought 814,606 shares of company stock worth $12,455,129 in the last three months. 10.40% of the stock is owned by corporate insiders.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP).
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
